Stock Traders Buy Large Volume of Heron Therapeutics Put Options (NASDAQ:HRTX)

Heron Therapeutics, Inc. (NASDAQ:HRTX) was the recipient of some unusual options trading activity on Wednesday. Investors purchased 41,908 put options on the company. This represents an increase of approximately 7,201% compared to the typical volume of 574 put options.

Wall Street Analyst Weigh In

A number of research firms have commented on HRTX. HC Wainwright downgraded shares of Heron Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 11th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Heron Therapeutics in a report on Friday, July 17th. Wall Street Zen upgraded shares of Heron Therapeutics to a “sell” rating in a research note on Saturday, August 8th. Finally, Zacks Research upgraded shares of Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, August 3rd. One research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $2.00.

Institutional Investors Weigh In On Heron Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Integrated Wealth Concepts LLC increased its stake in Heron Therapeutics by 67.5% in the 2nd quarter. Integrated Wealth Concepts LLC now owns 159,997 shares of the biotechnology company’s stock worth $68,000 after purchasing an additional 64,499 shares in the last quarter. Bank of America Corp DE purchased a new stake in Heron Therapeutics during the second quarter valued at about $46,000. Ieq Capital LLC purchased a new stake in Heron Therapeutics during the second quarter valued at about $41,000. Tejara Capital Ltd purchased a new stake in Heron Therapeutics during the second quarter valued at about $2,779,000. Finally, BlackRock Inc. acquired a new position in shares of Heron Therapeutics in the second quarter worth about $4,503,000. Institutional investors and hedge funds own 80.01% of the company’s stock.

Heron Therapeutics Price Performance

Heron Therapeutics stock traded down $0.02 during midday trading on Wednesday, hitting $0.38. The company’s stock had a trading volume of 1,232,294 shares, compared to its average volume of 2,524,296. The company has a quick ratio of 1.51, a current ratio of 2.49 and a debt-to-equity ratio of 24.35. The stock’s 50-day moving average price is $0.34 and its 200-day moving average price is $0.57. Heron Therapeutics has a 12 month low of $0.26 and a 12 month high of $1.57. The company has a market capitalization of $71.19 million, a PE ratio of -1.97 and a beta of 1.62.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Monday, August 10th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter. The business had revenue of $37.67 million during the quarter, compared to analyst estimates of $42.19 million. Heron Therapeutics had a negative return on equity of 293.02% and a negative net margin of 22.52%. Analysts anticipate that Heron Therapeutics will post -0.14 earnings per share for the current fiscal year.

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing medicines for acute care and oncology-related supportive care. The company’s products are designed to address patient needs in areas such as postsurgical pain and chemotherapy-induced nausea and vomiting.

Heron’s portfolio includes ZYNRELEF, an extended-release solution combining bupivacaine and meloxicam for the management of postsurgical pain, and APONVIE, an injectable formulation of aprepitant used to help prevent postoperative nausea and vomiting.